BMS-779788

CAS No. 918348-67-1

BMS-779788( XL-652 | BMS-788 | EXEL-04286652 )

Catalog No. M16592 CAS No. 918348-67-1

A potent, highly selective partial LXR agonist with Ki of 14 nM for LXRβ.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 41 In Stock
5MG 65 In Stock
10MG 88 In Stock
25MG 200 In Stock
50MG 295 In Stock
100MG 500 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BMS-779788
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent, highly selective partial LXR agonist with Ki of 14 nM for LXRβ.
  • Description
    A potent, highly selective partial LXR agonist with Ki of 14 nM for LXRβ, shows moderate selectivity (5-fold) over LXRα (Ki=68 nM); only has activity for PXR (ECU0=2 uM) in a panel of 14 NHRs; induces LXR target genes in blood in vivo (EC50=610 nM); increases in biliary cholesterol and decreases in phospholipid and bile acid in animal models.Atherosclerosis Phase 1 Clinical(In Vitro):The LXR selective partial agonist BMS-779788 is identified with potent induction of ATP binding transporters ABCA1 and ABCG1 in human whole blood (EC50=1.2 μM, 55% efficacy).(In Vivo):BMS-779788 induces LXR target genes in blood in vivo with an EC50=610 nM, a value similar to its in vitro blood gene induction potency. BMS-779788 is 29- and 12-fold less potent than the full agonist T0901317 in elevating plasma triglyceride and LDL cholesterol, respectively, with similar results for plasma cholesteryl ester transfer protein and apolipoprotein B. In mice BMS-779788 displays peripheral induction of ABCA1 at 3 and 10 mpk doses with no significant elevation of plasma or hepatic triglycerides at these doses, showing an improved profile compared to a full pan-agonist.
  • In Vitro
    The LXR selective partial agonist BMS-779788 is identified with potent induction of ATP binding transporters ABCA1 and ABCG1 in human whole blood (EC50=1.2 μM, 55% efficacy).
  • In Vivo
    BMS-779788 induces LXR target genes in blood in vivo with an EC50=610 nM, a value similar to its in vitro blood gene induction potency. BMS-779788 is 29- and 12-fold less potent than the full agonist T0901317 in elevating plasma triglyceride and LDL cholesterol, respectively, with similar results for plasma cholesteryl ester transfer protein and apolipoprotein B. In mice BMS-779788 displays peripheral induction of ABCA1 at 3 and 10 mpk doses with no significant elevation of plasma or hepatic triglycerides at these doses, showing an improved profile compared to a full pan-agonist.
  • Synonyms
    XL-652 | BMS-788 | EXEL-04286652
  • Pathway
    Nuclear Receptor/Transcription Factor
  • Target
    LXR
  • Recptor
    LXRα|LXRβ
  • Research Area
    Cardiovascular Disease
  • Indication
    Atherosclerosis

Chemical Information

  • CAS Number
    918348-67-1
  • Formula Weight
    509.0594
  • Molecular Formula
    C28H29ClN2O3S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: ≥ 31 mg/mL
  • SMILES
    CC(C)(C1=CC=CC=C1Cl)C2=NC(=CN2C3=CC=C(C=C3)C4=CC(=CC=C4)S(=O)(=O)C)C(C)(C)O
  • Chemical Name
    1H-Imidazole-4-methanol, 2-[1-(2-chlorophenyl)-1-methylethyl]-α,α-dimethyl-1-[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kick E, et al. Bioorg Med Chem Lett. 2015 Jan 15;25(2):372-7. 2. Kirchgessner TG, et al. J Pharmacol Exp Ther. 2015 Feb;352(2):305-14. 3. Adams ML, et al. J Pharm Sci. 2016 Apr;105(4):1478-88.
molnova catalog
related products
  • BMS-779788

    A potent, highly selective partial LXR agonist with Ki of 14 nM for LXRβ.

  • T0901317

    A potent, high affinity LXR agonist (EC50=50 nM, Kd are 7 and 22 nM for LXR-α and LXR-β respectively).

  • LXR-623

    A clinically viable, highly brain-penetrant LXRα-partial/LXRβ-full agonist with binding Ki of 33 nM/248 nM.